In modern metabolic and hormonal care, an important question is increasingly being asked: can GLP-1–based therapies such as Mounjaro be used safely and effectively alongside hormone replacement therapy (HRT)?
We are currently witnessing a major shift in the management of obesity, type 2 diabetes, and menopausal health.
GLP-1 receptor agonists are transforming metabolic care by promoting…
- Weight loss
- Improving insulin sensitivity
- Reducing cardiovascular risk.
At the same time, hormone replacement therapy remains central to managing menopausal symptoms and estrogen deficiency, with well-established benefits for bone health, fat distribution, and vascular function.
This article explores the individual roles of GLP-1 therapies and HRT, examines emerging evidence on their combined use, and discusses important clinical considerations when using them together.
Read the full article here: https://www.thelondonobesityclinic.co.in/mounjaro-or-glp-1-and-hormone-replacement-therapy-do-they-go-hand-in-hand/
